S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Top-Rated StocksTop-Rated
NASDAQ:ACLX

Arcellx (ACLX) Stock Forecast, Price & News

$35.88
-0.57 (-1.56%)
(As of 09/29/2023 ET)
Compare
Today's Range
$35.56
▼
$37.15
50-Day Range
$33.06
▼
$37.40
52-Week Range
$16.97
▼
$48.92
Volume
454,896 shs
Average Volume
391,322 shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.42
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Arcellx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
48.9% Upside
$53.42 Price Target
Short Interest
Bearish
17.71% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Arcellx in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$201,390 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.19) to ($1.87) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

670th out of 970 stocks

Biological Products, Except Diagnostic Industry

106th out of 157 stocks

See Top Rated MarketRank™ Stocks Here

ACLX stock logo

About Arcellx (NASDAQ:ACLX) Stock

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

ACLX Price History

ACLX Stock News Headlines

September 19, 2023 | markets.businessinsider.com
Analysts’ Top Healthcare Picks: Aclaris Therapeutics (ACRS), Incyte (INCY)
September 6, 2023 | seekingalpha.com
Arcellx: Clinical Hold Lifted, Charting A Brighter Path Forward (Rating Upgrade)
September 30, 2023 | Stansberry Research (Ad)
1907, 1929, 1998, 2007--and now 2023?
Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.
September 4, 2023 | finance.yahoo.com
Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade
August 20, 2023 | finance.yahoo.com
The Arcellx, Inc. (NASDAQ:ACLX) Analysts Have Been Trimming Their Sales Forecasts
August 17, 2023 | msn.com
Baird Maintains Arcellx (ACLX) Outperform Recommendation
August 17, 2023 | finance.yahoo.com
Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect?
August 16, 2023 | markets.businessinsider.com
Arcellx: Partial Clinical Hold Lifted By FDA On IMMagine-1 Phase 2 Trial; Q2 Net Loss Narrows
September 30, 2023 | Stansberry Research (Ad)
1907, 1929, 1998, 2007--and now 2023?
Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.
August 15, 2023 | markets.businessinsider.com
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
August 15, 2023 | msn.com
Needham Reiterates Arcellx (ACLX) Buy Recommendation
August 8, 2023 | benzinga.com
Arcellx Chief Medical Officer Trades $106K In Company Stock
July 31, 2023 | finance.yahoo.com
Arcellx's (NASDAQ:ACLX) investors will be pleased with their respectable 51% return over the last year
July 25, 2023 | finance.yahoo.com
Should You be Bullish on Arcellx (ACLX)?
July 6, 2023 | benzinga.com
Chief Medical Officer of Arcellx Makes $95K Sale
June 21, 2023 | seekingalpha.com
Arcellx's CAR-T Hold: Turmoil, Triumphs, And Trading Tips
June 20, 2023 | proactiveinvestors.com
Arcellx price target slashed, stock takes a hit as FDA puts hold on clinical trial following patient death
June 20, 2023 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
June 20, 2023 | markets.businessinsider.com
Analyst Ratings for Arcellx
June 20, 2023 | markets.businessinsider.com
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
June 20, 2023 | msn.com
Why Arcellx (ACLX) Stock Is Nosediving
June 20, 2023 | finance.yahoo.com
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
June 20, 2023 | nasdaq.com
Arcellx : FDA Places Clinical Hold On CART-ddBCMA IND For Treatment Of R/R Multiple Myeloma
June 20, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Arcellx Inc (ACLX)
May 28, 2023 | sg.finance.yahoo.com
Arcellx, Inc. (ACLX) stock price, news, quote & history – Yahoo Finance
May 18, 2023 | msn.com
The Latest Analyst Ratings for Arcellx
May 18, 2023 | msn.com
Truist Securities Initiates Coverage of Arcellx (ACLX) with Buy Recommendation
See More Headlines
Receive ACLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcellx and its competitors with MarketBeat's FREE daily newsletter.

ACLX Company Calendar

Last Earnings
8/14/2023
Today
9/30/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACLX
CUSIP
N/A
CIK
1786205
Web
arcellx.com
Phone
240-327-0603
Fax
N/A
Employees
98
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.42
High Stock Price Forecast
$104.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
+48.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-188,680,000.00
Net Margins
N/A
Pretax Margin
-568.13%
Return on Equity
-46.20%
Return on Assets
-25.29%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
3.57
Quick Ratio
3.57

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.68 per share
Price / Book
7.67

Miscellaneous

Outstanding Shares
48,360,000
Free Float
45,525,000
Market Cap
$1.74 billion
Optionable
Not Optionable
Beta
-0.68
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Rami Elghandour (Age 44)
    Chairman, CEO & Pres
    Comp: $1.02M
  • Ms. Michelle Lim Gilson (Age 30)
    Chief Financial Officer
    Comp: $832.8k
  • Dr. Christopher R. Heery M.D. (Age 43)
    Chief Medical Officer
    Comp: $688.55k
  • Mr. Michael Dombeck M.B.A.
    Chief Operating Officer
  • Mr. Narinderjeet Singh M.S. (Age 51)
    Chief Technical Officer
  • Mr. David Tice Ph.D. (Age 52)
    Chief Scientific Officer
  • Ms. Myesha Lacy
    VP of Investor Relations
  • Ms. Maryam Abdul-Kareem J.D.
    M.S., Gen. Counsel
  • Ms. Kate Aiken
    Chief People Officer
  • Mr. Neeraj P. Teotia (Age 48)
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ACLX Stock - Frequently Asked Questions

Should I buy or sell Arcellx stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcellx in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACLX shares.
View ACLX analyst ratings or view top-rated stocks.

What is Arcellx's stock price forecast for 2023?

10 equities research analysts have issued 1 year target prices for Arcellx's shares. Their ACLX share price forecasts range from $39.00 to $104.00. On average, they expect the company's stock price to reach $53.42 in the next year. This suggests a possible upside of 48.9% from the stock's current price.
View analysts price targets for ACLX or view top-rated stocks among Wall Street analysts.

How have ACLX shares performed in 2023?

Arcellx's stock was trading at $30.98 at the start of the year. Since then, ACLX shares have increased by 15.8% and is now trading at $35.88.
View the best growth stocks for 2023 here.

Are investors shorting Arcellx?

Arcellx saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 6,200,000 shares, a decline of 6.1% from the August 31st total of 6,600,000 shares. Based on an average trading volume of 440,500 shares, the short-interest ratio is currently 14.1 days. Currently, 17.7% of the company's stock are short sold.
View Arcellx's Short Interest.

When is Arcellx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACLX earnings forecast.

How were Arcellx's earnings last quarter?

Arcellx, Inc. (NASDAQ:ACLX) issued its earnings results on Monday, August, 14th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.18. The business had revenue of $14.30 million for the quarter, compared to analyst estimates of $82.38 million.

What ETFs hold Arcellx's stock?

ETFs with the largest weight of Arcellx (NASDAQ:ACLX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Fidelity Disruptive Medicine ETF (FMED).

When did Arcellx IPO?

(ACLX) raised $132 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 8,250,000 shares at $15.00-$17.00 per share.

What is Arcellx's stock symbol?

Arcellx trades on the NASDAQ under the ticker symbol "ACLX."

How do I buy shares of Arcellx?

Shares of ACLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcellx's stock price today?

One share of ACLX stock can currently be purchased for approximately $35.88.

How much money does Arcellx make?

Arcellx (NASDAQ:ACLX) has a market capitalization of $1.74 billion. The company earns $-188,680,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.

How can I contact Arcellx?

The official website for the company is arcellx.com. The company can be reached via phone at 240-327-0603 or via email at ir@arcellx.com.

This page (NASDAQ:ACLX) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -